Cargando…

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines

BACKGROUND: Among the epigenetic alterations occurring in cancer, DNA hypermethylation and histone hypoacetylation are the focus of intense research because their pharmacological inhibition has shown to produce antineoplastic activity in a variety of experimental models. The objective of this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chavez-Blanco, Alma, Perez-Plasencia, Carlos, Perez-Cardenas, Enrique, Carrasco-Legleu, Claudia, Rangel-Lopez, Edgar, Segura-Pacheco, Blanca, Taja-Chayeb, Lucia, Trejo-Becerril, Catalina, Gonzalez-Fierro, Aurora, Candelaria, Myrna, Cabrera, Gustavo, Duenas-Gonzalez, Alfonso
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1408081/ https://www.ncbi.nlm.nih.gov/pubmed/16448574 http://dx.doi.org/10.1186/1475-2867-6-2

Ejemplares similares

Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells
por: Pérez-Cárdenas, Enrique, et al.
Publicado: (2018)

Epigenetic therapy with hydralazine and valproate associated to cisplatin chemoradiation in FIGO stage IIIB. A phase II study
por: Candelaria, Myrna, et al.
Publicado: (2007)

DNA Methylation-Independent Reversion of Gemcitabine Resistance by Hydralazine in Cervical Cancer Cells
por: Candelaria, Myrna, et al.
Publicado: (2012)

Hydralazine target: From blood vessels to the epigenome
por: Arce, Claudia, et al.
Publicado: (2006)

A proof-of-principle study of epigenetic therapy with hydralazine and magnesium valproate plus doxorubicin cyclophosphamide as neoadjuvant therapy for locally advanced breast cancer
por: Arce, Claudia, et al.
Publicado: (2007)

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study
por: Chavez-Blanco, Alma, et al.
Publicado: (2005)

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
por: Candelaria, Myrna, et al.
Publicado: (2007)

A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes
por: Zambrano, Pilar, et al.
Publicado: (2005)

Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine
por: Segura-Pacheco, Blanca, et al.
Publicado: (2006)

A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer
por: Arce, Claudia, et al.
Publicado: (2006)

Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer
por: Taja-Chayeb, Lucia, et al.
Publicado: (2006)

Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid
por: Mora-García, María de Lourdes, et al.
Publicado: (2006)

Up-regulation of HLA class I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating hydralazine and the histone deacetylase inhibitor valproic acid
por: Mora-García, María de Lourdes, et al.
Publicado: (2007)

Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome
por: Taja-Chayeb, Lucia, et al.
Publicado: (2009)

Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer. Predictive and prognostic significance
por: Trejo-Becerril, Catalina, et al.
Publicado: (2005)

Polymorphisms of the thiopurine methyl transferase gene in healthy and acute lymphoblastic leukemia mestizos
por: Candelaria, Myrna, et al.
Publicado: (2007)

Antitumor Effects of Systemic DNAse I and Proteases in an In Vivo Model
por: Trejo-Becerril, Catalina, et al.
Publicado: (2016)

Cancer Progression Mediated by Horizontal Gene Transfer in an In Vivo Model
por: Trejo-Becerril, Catalina, et al.
Publicado: (2012)

Effects of the Histone Deacetylase Inhibitor Valproic Acid on Human Pericytes In Vitro
por: Karén, Jakob, et al.
Publicado: (2011)

Effects of histone deacetylase inhibitor valproic acid on skeletal myocyte development
por: Li, Qiao, et al.
Publicado: (2014)

A combination of inhibitors of glycolysis, glutaminolysis and de novo fatty acid synthesis decrease the expression of chemokines in human colon cancer cells
por: Schcolnik-Cabrera, Alejandro, et al.
Publicado: (2020)

Histone Deacetylases (HDAC) Inhibitor—Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor
por: Drzewiecka, Małgorzata, et al.
Publicado: (2023)

HER2 expression in cervical cancer as a potential therapeutic target
por: Chavez-Blanco, Alma, et al.
Publicado: (2004)

Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells
por: Stockhausen, M-T, et al.
Publicado: (2005)

Response to Hydralazine-Valproate in a Patient with Mycosis Fungoides
por: Dueñas-Gonzalez, Alfonso, et al.
Publicado: (2010)

ctDNA Is Useful to Detect Mutations at Codon 641 of Exon 16 of EZH2, a Biomarker for Relapse in Patients with Diffuse Large B-Cell Lymphoma
por: Díaz-Chávez, José, et al.
Publicado: (2022)

A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers
por: Bauman, Julie, et al.
Publicado: (2014)

Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro
por: ZHOU, YONG, et al.
Publicado: (2014)

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
por: Candelaria, Myrna, et al.
Publicado: (2021)

Cross-Species Functional Genomic Analysis Identifies Resistance Genes of the Histone Deacetylase Inhibitor Valproic Acid
por: Forthun, Rakel Brendsdal, et al.
Publicado: (2012)

Antimetastatic Effect of Epigenetic Drugs, Hydralazine and Valproic Acid, in Ras-Transformed NIH 3T3 Cells [Corrigendum]
Publicado: (2022)

HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo
por: Segura-Pacheco, Blanca, et al.
Publicado: (2007)

Migration, Proliferation, and Differentiation of Cord Blood Mesenchymal Stromal Cells Treated with Histone Deacetylase Inhibitor Valproic Acid
por: Marquez-Curtis, Leah A., et al.
Publicado: (2014)

HDAC (Histone Deacetylase) Inhibitor Valproic Acid Attenuates Atrial Remodeling and Delays the Onset of Atrial Fibrillation in Mice
por: Scholz, Beatrix, et al.
Publicado: (2019)

Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis
por: Laengle, Johannes, et al.
Publicado: (2020)

Histone deacetylase 2 inhibitor valproic acid attenuates bisphenol A-induced liver pathology in male mice
por: Al-Griw, Mohamed A., et al.
Publicado: (2022)

Molecular characterization of BRCA1 and BRCA2 genes in breast cancer patients under 40 years-old or with familiar cancer history
por: Millan, Silvia Vidal, et al.
Publicado: (2007)

Reversal of increased mammary tumorigenesis by valproic acid and hydralazine in offspring of dams fed high fat diet during pregnancy
por: Andrade, F. de Oliveira, et al.
Publicado: (2019)

A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma
por: Rocca, A, et al.
Publicado: (2009)

Histone Deacetylase Inhibitor Valproic Acid Promotes the Differentiation of Human Induced Pluripotent Stem Cells into Hepatocyte-Like Cells
por: Kondo, Yuki, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7vs3j61q6h3qusk3mk09j1uk18